{
  "url": "https://openlegislation.uk/national-security-and-investment-act-2021-notifiable-acquisition-specification-of-qualifying-entities-regulations-2021/schedule-16/paragraph-5",
  "json_url": "https://openlegislation.uk/national-security-and-investment-act-2021-notifiable-acquisition-specification-of-qualifying-entities-regulations-2021/schedule-16/paragraph-5.json",
  "legislation": "uksi/2021/1264",
  "legislation_title": "The National Security and Investment Act 2021 (Notifiable Acquisition) (Specification of Qualifying Entities) Regulations 2021",
  "legislation_url": "https://openlegislation.uk/national-security-and-investment-act-2021-notifiable-acquisition-specification-of-qualifying-entities-regulations-2021",
  "path": "schedule/16/paragraph/5",
  "kind": "paragraph",
  "number": "5",
  "heading": "Exceptions - general",
  "text": "Exceptions to the activities described in paragraph 2 are—\n(a) general services or servicing not related to core synthetic biology, where “core” means those activities without which experiments cannot be conducted, such as DNA synthesis or cloning;\n(b) the use of microorganisms to remove harmful contaminants, pollutants or toxins from the environment (known as bioremediation), including bio-based reagents that allow for testing for contaminants;\n(c) any approach used to gather clinical information for the purpose of making a clinical decision or making a diagnosis (known as diagnostics) but not the storage or ownership of sensitive human genetic information that enables the identification of an individual;\n(d) industrial biotechnology research, development or production using enzymes or organisms that have not been modified through the application of synthetic biology;\n(e) the production of substances ordinarily consumed as food or used as feed, including any ingredient or component of such substances;\n(f) gene therapy, where it is used solely for the purpose of replacing missing or defective genes to restore phenotypes to achieve a therapeutic effect;\n(g) cell therapy, where cells are modified by genetic engineering and then introduced into a patient to treat disease.",
  "extent": "E+W+S+N.I.",
  "status": null,
  "version": "current",
  "annotations": [
    {
      "type": "I",
      "label": "I1",
      "text": "Sch. 16 para. 5 in force at 4.1.2022, see reg. 1(2)"
    }
  ],
  "outstanding_effects": [],
  "provenance": {
    "source": "legislation.gov.uk",
    "source_url": "https://www.legislation.gov.uk/uksi/2021/1264/schedule/16/paragraph/5",
    "retrieved_at": "2026-10-28T22:07:12.670717+00:00"
  },
  "licence": "Open Government Licence v3.0",
  "licence_url": "https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/",
  "attribution": "Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives."
}